<!DOCTYPE html>
<html lang="en"><head>

<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1">

<meta name="format-detection" content="telephone=no" />

<link rel="icon" href="drive-icon.png" />
<link rel="apple-touch-icon" href="img/drive-apple-icon.png" />

<meta name="robots" content="index,follow" />

<meta name="keywords" content="" />
<meta name="description" content="DRIVe is transforming health security innovation to protect Americans from 21st century health security threats" />
<meta name="author" content="Barda DRIVe" />
<meta name="twitter:card" content="summary_large_image" />
<meta name="twitter:site" content="@BARDA" />
<meta name="twitter:title" content="DRIVe EZ-BAA" />
<meta name="twitter:description" content="BARDA DRIVe has a partnership opportunity for you." />
<meta name="twitter:image" content="https://drive.hhs.gov/img/ezbaa_twittercard.png" />
<meta name="twitter:image:alt" content="Banner for DRIVe EZ-BAA" />

<title>DRIVe</title>

<!-- Custom Fonts -->
<link href="https://fonts.googleapis.com/css?family=Raleway" rel="stylesheet">
<link href="font-awesome/css/font-awesome.min.css" rel="stylesheet" type="text/css">

<!-- Bootstrap Core CSS -->
<link href="css/bootstrap.min.css" rel="stylesheet">

<!-- Custom CSS -->
<link href="css/theme.css" rel="stylesheet">

<!-- HTML5 Shim and Respond.js IE8 support of HTML5 elements and media queries -->
<!-- WARNING: Respond.js doesn't work if you view the page via file:// -->
<!--[if lt IE 9]>
		<script src="/drivepubhtml/js/ie/html5shiv.js"></script>
		<script src="/drivepubhtml/js/ie/respond.min.js"></script>
	<![endif]-->

<!-- jQuery -->
<script src="js/jquery-min.js"></script>

<!-- Bootstrap Core JavaScript -->
<script src="js/bootstrap.min.js"></script>
	
<!-- Footer Include -->
	<script> 
    $(function(){
      $("#includefooter").load("footer.html"); 
    });
    </script> 
	
	<!-- Header Include -->
	<script> 
    $(function(){
      $("#includeheader").load("header.html"); 
    });
    </script> 

	
<!--- Non-GOV Website Dialog popup -->	
<script src="js/confirmExit.js"></script>

<script>
	$(function() {
		$('[data-toggle="tooltip"]').tooltip();
	})
	
	function scrollRelativeTo(id, px) {
		var x = $(id).position();
	    window.scrollTo(x.left, x.top + px)
	}
	
	$(document).ready(function() {
		var scrollFactor = -100;
		var href = window.location.href;
		if (href.endsWith("id=applyNow")) {
			scrollRelativeTo("#applyNow", scrollFactor);
		}
		else if (href.endsWith("id=partneringApproaches")) {
			scrollRelativeTo("#partneringApproaches", scrollFactor);
		}

	});
</script>




</head>

<body id="page-top" class="index">
	<!-- Google Tag Manager -->
	<script>
		(function(i, s, o, g, r, a, m) {
			i['GoogleAnalyticsObject'] = r;
			i[r] = i[r] || function() {
				(i[r].q = i[r].q || []).push(arguments)
			}, i[r].l = 1 * new Date();
			a = s.createElement(o), m = s.getElementsByTagName(o)[0];
			a.async = 1;
			a.src = g;
			m.parentNode.insertBefore(a, m)
		})(window, document, 'script',
				'https://www.google-analytics.com/analytics.js', 'ga');

		ga('create', 'UA-122497508-1', 'auto');
		ga('send', 'pageview');
	</script>
	<!-- End Google Tag Manager -->

    <!-- Navigation -->
	<div id="includeheader"></div>
    <!-- End Navigation -->
	
   
	<!-- Header -->
	<!-- Header -->
	<header style="border-bottom: 1px solid #efefef; padding-bottom: 20px;" id="banner">
		<div class="jumbotron services"
			style="background-color: #FFFFFF;">
			<div class="container">
				<div class="row">
					<div class="col-lg-12 banner-text-container">
						<div class="banner-text">
							<div class=" green">
								<div class="home-banner-heading">
									<h3 class="title" style="letter-spacing: 8px; color: #282828; font-size: 40px; text-transform: none;" >BARDA DRIVe EZ-BAA</h3><br />
</div>
							</div>
						</div>
					</div>
				</div>
			</div>
		</div>
	</header>
		<br><br>
	
	<!--parterships gray boxes -->	
	<link href="css/grayscale.css" rel="stylesheet" type="text/css">
		
	<!-- Font Awesome Version 5.0 -->
	<link rel="stylesheet" href="https://use.fontawesome.com/releases/v5.5.0/css/all.css" integrity="sha384-B4dIYHKNBt8Bc12p+WXckhzcICo0wtJAoU8YZTY5qE0Id1GSseTk6S+L3BlXeVIU"
	 crossorigin="anonymous">
	

	</header>
    <br>
	<section>
			<div id="ncov" class="container">
				<div  id="apply" class="row">
					<div class="col-xs-12 text-center">
					  <h5>We <b>partner with companies and teams</b> offering solutions to a broad range of <strong>national health security threats</strong>. DRIVe partnering approaches vary depending on the project. DRIVe has two main solicitations, our EZ-BAA for awards under $749K and our BAA Special Instructions for larger projects.</h5>
					</div>
				</div>
			</div>
		</section><br>
	
		<section>
			<div class="container">
				<div class="row">
					<div class="col-md-12 text-center">
					  <h5 id="ecmo" style="font-size: 25px">For additional details about the COVID-19 response, please visit the <a href="https://www.cdc.gov/coronavirus/2019-ncov/index.html" target="_blank">CDC website</a></h5>
					</div>
				</div>
			</div>
		</section><br>
	
	<!--
		<section style="background-color: #f5f5f5;">
		<div  class="container">
			<div class="row">
				<div class="col-lg-6">
					
					<h2 style=" margin-top: 30px; font-size: 40px; text-transform: none; border-left: #428230 3px solid;">ECMO RFI is now live!
						
						</h2>

					<p style=" padding-top: 20px;">BARDA DRIVe is seeking information on developments in anticoagulation drugs, assays, and management in the specific context of extracorporeal life support, specifically <strong>extracorporeal membrane oxygenation (ECMO)</strong>. Our goal is to gain an understanding of present and future capabilities in this field. Through this Request for Information (RFI), BARDA DRIVe intends to identify areas of innovation that can <strong>solve the challenges posed by anticoagulation in ECMO</strong> or <strong>improve on the ways this issue is currently being addressed</strong>. We also hope to connect with stakeholders and key opinion leaders, who would have an interest in responding to this RFI or in engaging with DRIVe on the topic of ECMO and anticoagulation.  </p>
				<p><strong>Interested parties should read the RFI in full and submit their response to <a href="DRIVeContracting@hhs.gov">DRIVeContracting@hhs.gov</a> by 11:00AM ET on May 18th, 2021. </strong></p><br>
				<a  class="btn-info" style="padding:10px" target="_blank" href="/files/RFI-21-BARDA-0001_Anticoagulation_and ECMO-2.pdf">Download RFI</a><br><br>
				</div>
				<div id="applynownav" class="col-lg-6">
				<div class="container">
						<div class="row">
							<img style="margin-top: 20px;" class="img-fluid" src="img/redcells_traveling.jpeg">
						</div> 
					</div>
				</div>
			</div>
		</div>
	</section>

	-->
<br>
	
<hr />
<br>
	<section>
		<div class="container">
	
	<h4 class="text-center">DRIVe EZ-BAA (BAA-20-100-SOL-0002)</h4>
			<br>
			<p>Pursuant to FAR 35.016(c), the official posting of the broad agency announcement is available on beta.sam.gov and can be found here: <a href="https://sam.gov/opp/9623a33bc323406d82670ce1d830ffcd/view" target="_blank">BAA-20-100-SOL-0002</a>. The announcement as it is posted on beta.sam.gov serves as the official Governmentwide point of entry (GPE). The content below is information directly from the GPE and is provided here for ease of reference only. In the event of any conflict or inconsistency between information on the GPE and the below information, the information found on the GPE shall control.
 </p>
			
<br>
			
<h5><strong>AOI’s Currently Accepting Submissions: :</strong></h5>
			<p>Unless otherwise noted below, open AOI’s are accepting submissions throughout the EZ-BAA open period which ends 03 February 2023, 1700 HRS ET. BARDA reserves the right to revise the status of submission periods for any of the AOI’s or the EZ-BAA itself. Any change to open periods for submissions will be posted in the form of an amendment / special instruction to the EZ-BAA.</p><br>
<ul>
<li>AOI #2: Infection Severity & Solving Sepsis (<a href="mailto:SolvingSepsis@hhs.gov" target="_blank">SolvingSepsis@hhs.gov</a>)</li>

	
	
<li>AOI #6: Beyond the Needle (<a href="mailto:BeyondTheNeedle@hhs.gov" target="_blank">BeyondTheNeedle@hhs.gov</a>)</li>
<li>AOI #7: ImmuneChip+ (<a href="mailto:ImmuneChipBARDA@hhs.gov" target="_blank">ImmuneChipBARDA@hhs.gov</a>) <strong>[Currently Paused]</strong></li> 
<li>AOI #8: Bringing Laboratory Testing to the Home (<a href="mailto:homediagnostics@hhs.gov" target="_blank">homediagnostics@hhs.gov</a>)</li>
<li>AOI #9: Digital Health Tools for Pandemic Preparedness (<a href="mailto:digitalhealth@hhs.gov" target="_blank">digitalhealth@hhs.gov</a>)</li>
<li>AOI #10: NGS-based Agnostic Diagnostic (<a href="mailto:NGS@hhs.gov" target="_blank">NGS@hhs.gov</a>)</li>
<li>AOI #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 (<a href="mailto:COVID19_homeDx@hhs.gov" target="_blank">COVID19_homeDx@hhs.gov</a>)</li>
<li>AOI #11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection (<a href="mailto:COVID19_homeDx@hhs.gov" target="_blank">COVID19_homeDx@hhs.govv</a>)</li>
 
	 </ul>	
			<hr /><br>
	<h5 style="color: #6C6C6C;"><strong>Closed AOIs: </strong></h5>
			<ul style="color: #6C6C6C;">
				<li>AOI #1: ENACT (Early Notification to Act, Control and Treat)</li>   

	<li>AOI #3: Other Disruptive Innovations <!--[Paused]--></li>
	<li>AOI #4: COVID-19</li>
	<li style="margin-left: 20px">AOI #4.1-A Molecular Diagnostic Assay for SARS-CoV-2 virus on existing FDA-cleared platform <!--[CLOSED--></li>
	<li style="margin-left: 20px">AOI #4.1-B Point-of-Care Diagnostic Assay for detection of SARS-CoV-2 virus <!--[CLOSED]--></li>
	<li style="margin-left: 20px">AOI #4.1-C: Diagnostic Assay for detection of COVID-19 disease <!--[CLOSED]--></li>

<li style="margin-left: 20px">AOI #4.1-D: Remote Patient Monitoring/Remote Diagnostic Tools </li>
<li style="margin-left: 20px">AOI #4.1-E: Pediatric Diagnostic Tools for Severe COVID-19 Disease and MIS-C</li>
<li>AOI #4.2: Nonclinical Model Development and Screening for SARS-CoV-2 virus <!--[CLOSED]--></li>
<li>AOI #4.3: Alternative Routes of Administration (AROA) for Vaccines  [Re-established as AOI#6: Beyond the Needle] </li>
<li>AOI #4.4: Advanced Manufacturing Technologies <!--[CLOSED]--></li>
<li>AOI #5: ReDIRECT (Repurposing Drugs In Response to Chemical Threats)<!--[CLOSED]--> </li>

			
			
			
			</ul>
	
			<br>
		<hr />			
			
<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>BARDA DRIVe EZ-BAA Document – Originally Posted February 3rd, 2020 </strong> - This Easy Broad Agency Announcement (EZ-BAA) sets forth areas of interest (AOIs) for the Division of Research, Innovation, and Ventures (DRIVe) in the Office of Biomedical Advanced Research and Development Authority (BARDA), issued under paragraph 6.102(d)(2)(i) of the Federal Acquisition Regulation (FAR). Abstract submissions selected for award are considered to be the result of full and open competition and in full compliance with 41 U.S.C. § 3301.</p>
		</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA.pdf">DRIVe EZ-BAA.pdf</a>
	</div>
	
			</div>
	<br>
			<hr />
			<br>
	<h4 class="text-center">Amendments & Special Instructions to the DRIVe EZ-BAA</h4><br>
		<p class="text-center">In addition to reading the full EZ-BAA Document carefully, which is found above (<a href="files/ezbaa_files/DRIVe_EZ-BAA.pdf" target="_blank">DRIVE EZ-BAA.pdf</a>), please read each of the following amendments / special instruction documents and corresponding descriptions to understand how specific guidelines for each of the research areas.
 </p>	
	
<div class="row">
	<div class="col-lg-8 text-left"><br><br>
		<p><strong>Special Instructions #1 - 2/3/2020</strong> - Please see Special Instructions 001 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions, BARDA is temporarily suspending AOIs 1-3 as part of its EZ-BAA (BAA-20-100-SOL-0002), but is pleased to announce that it is now accepting abstract submissions for AOI #4: 2019-nCoV.</p>
	</div><br><br>
	<div class="col-lg-3"><br><br>
		<a target="_blank" href="files/ezbaa_files/DRIVE_EZ-BAA_Amendment_001.pdf">DRIVe EZ-BAA - Special Instructions 001.pdf</a>
	</div>
	</div>
	<hr />
		
	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>Special Instructions #2 - 2/15/2020</strong> - Please see Special Instructions 002 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions, BARDA is adding a new topic under its temporary AOI #4:  2019-nCoV as part of its EZ-BAA (BAA-20-100-SOL-0002).</p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_002.pdf">DRIVe EZ-BAA - Special Instructions 002.pdf</a>
	</div>
	</div>
	<hr />		
	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>Special Instructions #3 - 3/9/2020</strong> - Please see Special Instructions 003 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions, BARDA is adding several new topics under its temporary AOI #4: COVID-19 (renamed from 2019-nCoV) as part of its EZ-BAA (BAA-20-100-SOL-0002).</p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_003.pdf">DRIVe EZ-BAA - Special Instructions 003.pdf</a>
	</div>
	</div>
	<hr />		

	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>Special Instructions #4 - 3/18/2020</strong> - Please see Special Instructions 004 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 004, BARDA is closing topic #4.2 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).  </p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_004.pdf">DRIVe EZ-BAA - Special Instructions 004.pdf</a>
	</div>
	</div>
	<hr />		
	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>Special Instructions #5 - 4/2/2020</strong> - Please see Special Instructions 005 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 005, BARDA is closing topic #4.1-A and revising topic #4.1-C under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).  </p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_005.pdf">DRIVe EZ-BAA - Special Instructions 005.pdf</a>
	</div>
	</div>
	<hr />		
	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>Special Instructions #6 - 4/27/2020</strong> - Please see Special Instructions 006 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 006, BARDA is adding topic #4.1-D under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).  </p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_006.pdf">DRIVe EZ-BAA - Special Instructions 006.pdf</a>
	</div>
	</div>
	<hr />	
			
	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>Special Instructions #7 - 5/12/2020</strong> - Please see Special Instructions 007 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 007, BARDA is closing topics #4.1-B and #4.1-C under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). </p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_007.pdf">DRIVe EZ-BAA - Special Instructions 007.pdf</a>
	</div>
	</div>
	<hr />		
	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong>Special Instructions #008 / Amendment #1 - 6/4/2020</strong> - Amendment 001 to the EZ-BAA is now included as an attachment.  Amendment 001 revises Section C of the EZ-BAA.  </p>
		<p>Please also see Special Instructions 008 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 008, BARDA is revising topic #4.3 immediately, and closing topic #4.4 at 1700 HRS ET on 05 June 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002). </p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_008.pdf">DRIVe EZ-BAA - Special Instructions 008.pdf</a>
	</div>
	</div>
	<hr />		
			
<div class="row">
	<div class="col-lg-8"><br>
		<p><strong> Special Instructions #9 - 6/29/2020</strong> - Please see Special Instructions 009 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 009, BARDA is revising topics #4.1-D and #4.3 immediately, and extending the closing date to 2359 HRS ET on 31 October 2020 under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).</p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_009.pdf">DRIVe EZ-BAA - Special Instructions 009.pdf</a>
	</div>
	</div>
	<hr />	
		
	<div class="row">
	<div class="col-lg-8"><br>
		<p><strong> Special Instructions #10 - 7/9/2020</strong> - Please see Special Instructions 010 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 010, BARDA is adding topic #4.1-E under its temporary AOI #4: COVID-19 as part of its EZ-BAA (BAA-20-100-SOL-0002).</p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_010.pdf">DRIVe EZ-BAA - Special Instructions 010.pdf</a>
	</div>
	</div>
	<hr />
		<div class="row">
	<div class="col-lg-8"><br>
	<p><strong> Special Instructions #11 - 10/1/2020</strong> - Please see Special Instructions 011 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 011, BARDA is now accepting abstract submissions for "Area of Interest #5: ReDIRECT (Repurposing Drugs In Response to Chemical Threats)" as part of its EZ-BAA (BAA-20-100-SOL-0002).</p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_011.pdf">DRIVe EZ-BAA - Special Instructions 011.pdf</a>
	</div>
	</div>
	<div class="row">
	<div class="col-lg-8 text-left"><br><br>
		<p><strong>Special Instructions #12 - 10/22/2020</strong> - Please see Special Instructions 012 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002. Under these Special Instructions 012, BARDA is now accepting abstract submissions for "AOI #1: ENACT  (Early Notification to Act, Control and Treat)” and "AOI#2: Infection Severity & Solving Sepsis.” Additionally, “AOI #4.3:  Alternative Routes of Administration (AROA) for Vaccines” is now “AOI #6: Beyond the Needle".</p>
	</div><br><br>
	<div class="col-lg-3"><br><br>
		<a target="_blank" href="files/ezbaa_files/DRIVe_EZ-BAA_Special_Instructions_012.pdf">DRIVe EZ-BAA - Special Instructions 012.pdf</a>
	</div>
	</div>
	<hr />
		<div class="row">
	<div class="col-lg-8"><br>
	<p><strong> Special Instructions #13 - 6/30/2021</strong> - Please see Special Instructions 013 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 013, BARDA is now accepting abstract submissions for Area of Interest #7: ImmuneChip+ as part of its EZ-BAA (BAA-20-100-SOL-0002).</p>
	</div>
	<div class="col-lg-3"><br>
		<a target="_blank" href="files/DRIVe_EZ-BAA_Special Instructions_013_Updated.pdf">DRIVe EZ-BAA - Special Instructions 013.pdf</a>
	</div>
	</div>
	<div class="row">
		<div class="col-lg-8"><br>
		<p><strong> Special Instructions #14 - 8/25/2021</strong> - Please see Special Instructions Special Instructions 014 Issuance for Easy Broad Agency Announcement (EZ-BAA) BAA-20-100-SOL-0002.  Under these Special Instructions 014, BARDA is now accepting abstract submissions for Area of Interest #8: Bringing Laboratory Testing to the Home, #9: Digital Health Tools for Pandemic Preparedness, #10: NGS-based Agnostic Diagnostic, #11a: Home-based, Over-the-Counter Diagnostics for the Detection of SARS-CoV-2 and 11b: Enabling Technologies to Support Home-Based Diagnostics for SARS-CoV-2 Acute Infection as part of its EZ-BAA (BAA-20-100-SOL-0002).</p>
		</div>
		<div class="col-lg-3"><br>
			<a target="_blank" href="files/DRIVe_EZ_BAA_Special_Instructions_014.pdf">DRIVe EZ-BAA - Special Instructions 014.pdf</a>
		</div>
		</div>

	</div>
	</section>
	
	
	
	
<hr />
	
	
	<section>
<div class="container">
	<div><br><h4 class="text-center">How to Apply & What to Expect</h4><br></div>
    <div class="row mx-auto">   
       
            <div class="col-md-6">
            <div class="pricingTable">
                <div class="pricingTable-header">
                  <h3>EZ-BAA-20-100-SOL-0002</h3>
                </div>
 
                <div class="pricingContent">
                    <ul>
                        <li>Awards under $750K</li>
                        <li>Emerging Disruptive Ideas</li>
                        <li>Simplified Abstract</li>
                        <li>30-120 Day Review Target</li>
                    </ul>
                </div><!-- /  CONTENT BOX-->
 
                <div class="pricingTable-sign-up">
                    <a href="https://drive.rti.org/" class="btn btn-dark" target="_blank">Apply Now</a>
                </div><!-- BUTTON BOX-->
            </div>
        </div>
		<div class="col-md-6">
			<div class="container">
						<div class="row">
								<ol class="list-arrows  numbers">
									<li>Review the solicitation on <a href="https://sam.gov/opp/73eaa41ada0d4bd6977e72ccb2f191d4/view" target="_blank">beta.SAM.gov.</a>*</li>
									<li>Request an account on the <a
										href="https://drive.rti.org/" target="_blank">EZ-BAA Portal</a>.</li>
									
									<li>Once your account is active, complete the online abstract via the Portal.</li>
									<li>BARDA personnel will review your abstract as described in the solicitation.</li>
									
								</ol> 
			
						
						</div> 
					</div>
		
		</div>
		<div class="mx-auto"><br><p>*Award amounts may differ depending on award structure and/or availability of funding</p>
        </div>
    </div>
	</div>
	</section>
	
	<hr />
	
	
		<section>
<div class="container">
	<div><br><h4 class="text-center">Straightforward & Transparent Review Proces</h4><br></div>
    <div class="row mx-auto">   
       
            <div class="col-md-6">
            <div>
            <br><br>
 
                <div>
					<ul>
 <li>Streamlined broad agency announcement (“BAA”)</li>
<li>Simplified application process</li>
<li>Projects under $750,000</li>
<li>Cost-share element</li>
</ul>
                </div><!-- /  CONTENT BOX-->
 
            
            </div>
        </div>
		<div class="col-md-6">
			<div class="container">
						<div class="row">
								
			<img class="img-fluid" src="img/DRIVe_Review_Process.png">
						
						</div> 
					</div>
		
		</div>
		
    </div>
	</div>
	</section>
	


	<!--   END: CONTENT -->

	<!-- Footer -->
 <div id="includefooter"></div>
<!-- Footer --------->

	<!-- Scroll to Top Button (Only visible on small and extra-small screen sizes) -->
	<div id="scroll-top-link"
		class="scroll-top page-scroll visible-xs visible-sm">
		<a class="btn btn-primary" href="#page-top"> <i
			class="fa fa-chevron-up"></i>
		</a>
	</div>

	<script>
		$(document).on("scroll", function() {
			if ($(document).scrollTop() > 100) {
				$(".navbar-fixed-top").addClass("navbar-shrink");
				$(".navbar-brand").addClass("navbar-brand-shrink");
			} else {
				$(".navbar-fixed-top").removeClass("navbar-shrink");
				$(".navbar-brand").removeClass("navbar-brand-shrink");
			}
		});
	</script>
</body>

</html>

